<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234429</url>
  </required_header>
  <id_info>
    <org_study_id>1839IL/0143</org_study_id>
    <nct_id>NCT00234429</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of Tomudex &amp; Iressa as Second Line Chemotherapy in Subjects With Colorectal Carcinoma</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blind Phase 2b Study of Raltitrexed (Tomudex) and ZD1839 (Iressa) Versus Raltitrexed Alone as Second Line Chemotherapy in Subjects With Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the activity of raltitrexed and ZD1839&#xD;
      versus raltitrexed alone as second line chemotherapy in subjects with colorectal carcinoma by&#xD;
      estimating progression free survival (PFS) in each treatment arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the progression free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine objective tumor response</measure>
  </secondary_outcome>
  <enrollment>74</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefitinib, raltitrexed</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 18 to 75 years, inclusive&#xD;
&#xD;
          -  histologically-confirmed metastatic colorectal carcinoma; measurable lesion according&#xD;
             to the Response Evaluation Criteria in Solid Tumours (RECIST)&#xD;
&#xD;
          -  relapsed after treatment with a fluoropyrimidine-based chemotherapy&#xD;
&#xD;
          -  prior chemotherapeutic regimen for metastatic or locally advanced disease with an&#xD;
             interval of at least 4 weeks between the last administration of chemotherapy an the&#xD;
             first administration of study treatment&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          -  life expectancy of at least 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known severe hypersensitivity to raltitrexed or any of the excipients of this product&#xD;
&#xD;
          -  known severe hypersensitivity to raltitrexed or any of the excipients of this product&#xD;
&#xD;
          -  active infection or uncontrolled diarrhoea&#xD;
&#xD;
          -  cerebral metastasis or meningeal carcinomatosis&#xD;
&#xD;
          -  any evidence of clinically active interstitial lung disease (patients with chronic&#xD;
             stable radiographic changes who are asymptomatic need not be excluded)&#xD;
&#xD;
          -  simultaneous antitumoral treatment&#xD;
&#xD;
          -  radiotherapy within 2 weeks before entry into the study&#xD;
&#xD;
          -  other co-existing malignancies or malignancies diagnosed within the last 5 years with&#xD;
             the exception of basal cell carcinoma or cervical cancer in situ&#xD;
&#xD;
          -  any unresolved chronic toxicity greater than common toxicity criteria (CTC) grade 2&#xD;
             from previous anticancer therapy (except alopecia)&#xD;
&#xD;
          -  significant clinical disorder or laboratory finding (leukocyte count less than 3.0 x&#xD;
             109 /litre (L) or platelets less than 100 x 109 /L; serum total bilirubin more than&#xD;
             2.0 mg/dl; as judged by investigator, any evidence of severe or uncontrolled systemic&#xD;
             disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal&#xD;
             disease); creatinine clearance â‰¥ 65ml/min (according to Cockcroft-Gault formula);&#xD;
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 2&#xD;
             times the upper limit of the reference range (ULRR) if no demonstrable liver&#xD;
             metastases, or greater than 5 times the ULRR in the presence of liver metastases)&#xD;
&#xD;
          -  pregnancy or breast feeding (women of child-bearing potential)&#xD;
&#xD;
          -  concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or ST John's&#xD;
             Wort;&#xD;
&#xD;
          -  Treatment with a non- approved or investigational drug within 30 days before Day 1 of&#xD;
             study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca Spain Medical Director, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gijon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pamplona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>October 5, 2005</study_first_submitted>
  <study_first_submitted_qc>October 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2005</study_first_posted>
  <last_update_submitted>December 14, 2007</last_update_submitted>
  <last_update_submitted_qc>December 14, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2007</last_update_posted>
  <keyword>Colorectal carcinoma advanced disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

